Abstract: . . .  syndrome are at increased risk for recurrence despite having a therapeutic INR value (Hirsh et al., 2002). References Hirsh J, Lee AYY. Blood 99 :3102- 3110. However, as the risk of bleeding in general during therapy is high, lifelong treatment with anticoagulants is not generally recommended after a first episode of venous thrombosis . 2002. How we diagnose and treat deep vein thrombosis . C:\Documents and Settings\zzz6\Local Settings\Temporary . . .
. . .  increased risk for recurrence despite having a therapeutic INR value (Hirsh et al., 2002). References Hirsh J, Lee AYY. Blood 99 :3102- 3110. However, as the risk of bleeding in general during therapy is high, lifelong treatment with anticoagulants is not generally recommended after a first episode of venous thrombosis . 2002. How we diagnose and treat deep vein thrombosis . C:\Documents and Settings\zzz6\Local Settings\Temporary Internet . . .
. . .  anticoagulation among homozygous individuals with the factor V Leiden mutation or among individuals either homozygous or heterozygous for the prothrombin 20210A mutation. Sarasin et al. (1998) developed a decision analysis model to determine the risks and benefits of stopping oral anticoagulation after three months, with re-initiation only after recurrent thrombosis , versus extending oral anticoagulation up to one to five years. The hypothetical cohort consisted of  . . .
. . .  with anticoagulants is not generally recommended after a first episode of venous thrombosis . 2002. How we diagnose and treat deep vein thrombosis . C:\Documents and Settings\zzz6\Local Settings\Temporary Internet Files\OLK107\1CLINICAL UTILITY.doc 2004-7  . . .
. . .  anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Prandoni P, Lensing A, Cogo A, Cuppini S, Villalta S, Carta M, The long-term clinical course of acute deep venous thrombosis . van der Meer FJM, Rosendaal FR, Vandenbroucke JP, Briet E. Bleeding complications in An analysis of risk factors. Arch Intern Med Simonneau G, Sors H, Charbonnier B, Page Y, Laaban JP, . . .
. . .  Bleeding complications in An analysis of risk factors. Arch Intern Med Simonneau G, Sors H, Charbonnier B, Page Y, Laaban JP, Azarian R, et al. 1997. A comparison of low molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans lEmbolie Pulmonaire. N Engl J Med 337 :663-669. C:\Documents and Settings\zzz6\Local Settings\Temporary Internet Files\OLK107\1CLINICAL . . .
--3000,6,250,3229,20577